Research To Practice | Oncology Videos

Latest Episodes:

Small Cell Lung Cancer | Oncology Today with Dr Neil Love: Management of Patients with Small Cell Lung Cancer Oct 06, 2022

Show notes

Featuring perspectives from Dr Benjamin Levy, including the following topics:

Disease biology of and therapeutic strategies for small cell lung cancer (SCLC) (0:00)
Current and future management of limited-stage SCLC (3:32)
Case: A man in his mid 70s with newly diagnosed SCLC and isolated brain metastases (5:51)
Novel therapies for SCLC (21:51)
Future directions for lurbinectedin in the treatment of SCLC (25:54)
Case: A man in his late 40s with no smoking history diagnosed with adenocarcinoma of the lung with EGFR exon 19, TP53 and RB1 mutations and small cell transformation apparent on repeat biopsy (29:54)
Case: A man in his mid 50s with a heavy smoking history diagnosed with SCLC and disease progression after anti-PD-L1 monotherapy (36:25)
Expanding immunotherapy options for the treatment of SCLC (41:07)
Palliative and supportive services for patients with SCLC (44:21)

CME information and select publications

Oncology Today: Management of Endometrial Cancer Oct 04, 2022

Show notes

Featuring an interview with Dr Michael Birrer, including the following topics:

Prologue (0:00)
Multidisciplinary Management of Endometrial Cancer in Copenhagen, Denmark; Boston, Massachusetts and Little Rock, Arkansas (6:17)
Subtypes of Endometrial Cancer (12:51)
Treatment for Microsatellite Instability-High Endometrial Cancer (16:27)
Microsatellite-Stable Endometrial Cancer (37:26)
Future Directions in the Treatment of Endometrial Cancer (49:29)

CME information and select publications

Multiple Myeloma | Oncology Today with Dr Neil Love: BCMA-Directed Therapies for Multiple Myeloma (Companion Faculty Lecture) Sep 29, 2022

Show notes

Featuring a slide presentation and related discussion from Dr Amrita Krishnan, including the following topics:

Key efficacy and safety data with belantamab mafodotin for multiple myeloma (MM) (0:00)
Guidelines for the prevention and management of keratopathy in patients receiving belantamab mafodotin (3:46)
Belantamab mafodotin in combination with pomalidomide; recent data and ongoing trials with BCMA-targeted bispecific antibodies (7:30)
BCMA-targeted CAR (chimeric antigen receptor) T-cell therapies under evaluation for MM (17:07)

CME information and select publications

Multiple Myeloma | Oncology Today with Dr Neil Love: BCMA-Directed Therapies for Multiple Myeloma Sep 29, 2022

Show notes

Featuring an interview with Dr Amrita Krishnan, including the following topics:

Case: A woman in her early 60s who presents with renal failure and receives CyBorD for multiple myeloma (MM) (0:00)
Dyspnea associated with carfilzomib; ocular toxicity with belantamab mafodotin (6:26)
Efficacy, tolerability and sequencing of belantamab mafodotin for MM; myths and misperceptions (10:33)
Case: A man in his early 70s who presents with back pain and compression fractures; efficacy of bispecific antibodies compared to chimeric antigen receptor (CAR) T-cell therapy (17:40)
Emerging data with the GPRC5D-targeted bispecific antibody talquetamab; similarities and differences in the pharmacology of BCMA-targeted bispecific antibodies for MM (25:31)
Case: A man in his mid 50s who presents with severe back pain and an L5 mass (30:22)
Diagnosis and management of cytokine release syndrome, neurotoxicity and infectious complications with CAR T-cell therapy (35:05)
Future roles of bispecific antibodies, CAR T-cell therapy and transplantation in the treatment of MM; eligibility criteria for patients to receive CAR T-cell therapy (44:06)

CME information and select publications

Non-Small Cell Lung Cancer | Oncology Today with Dr Neil Love: Management of Localized Non-Small Cell Lung Cancer Sep 26, 2022

Show notes

Featuring an interview with Dr Heather Wakelee, including the following topics:

Similarities and differences in the efficacy of neoadjuvant and adjuvant immunotherapies for localized non-small cell lung cancer (NSCLC) (0:00)
Available data on the treatment of patients whose disease relapses on or after adjuvant immunotherapy (6:15)
Activity of immunotherapy in patients whose tumors are EGFR mutated (10:29)
Case: A woman in her mid 70s with EGFR-mutated NSCLC in her right lung (14:49)
Case: A woman in her early 60s with a smoking history and a 4-cm right lower lobe lesion (24:17)
Case: A man in his mid 50s with a smoking history and a left upper lobe mass with high PD-L1 expression (28:04)
Optimal treatment of localized NSCLC in patients who have alterations in RET, BRAF and ALK (33:08)
Importance of primary care doctors screening their patients for lung cancer (37:03)

CME information and select publications

Non-Small Cell Lung Cancer | Oncology Today with Dr Neil Love: Management of Localized Non-Small Cell Lung Cancer (Companion Faculty Lecture) Sep 26, 2022

Show notes

Featuring a slide presentation and related discussion from Dr Heather Wakelee, including the following topics:

Key efficacy and safety data with belantamab mafodotin for multiple myeloma (MM) (0:00)
Guidelines for the prevention and management of keratopathy in patients receiving belantamab mafodotin (3:46)
Belantamab mafodotin in combination with pomalidomide; recent data and ongoing trials with BCMA-targeted bispecific antibodies (7:30)
BCMA-targeted CAR (chimeric antigen receptor) T-cell therapies under evaluation for MM (17:07)

CME information and select publications

Ovarian Cancer | Meet The Professor: Optimizing the Management of Ovarian Cancer — Part 4 Sep 23, 2022

Show notes

Featuring perspectives from Dr Richard Penson, including the following topics:

Introduction: Journal Club with Richard T Penson, MD, MRCP (0:00)
Case: A woman in her mid 70s with Stage IIIB BRCA wild-type, high-grade serous ovarian cancer (HGSOC) who receives neoadjuvant and adjuvant carboplatin/paclitaxel and develops severe thrombocytopenia on maintenance niraparib — Gigi Chen, MD (12:28)
Case: A woman in her late 30s with Stage IIC BRCA wild-type HGSOC who undergoes surgery and receives carboplatin/paclitaxel (LOH-negative) — Dana M Chase, MD (24:39)
Case: A woman in her early 60s with Stage IIIC HGSOC and a germline BRCA1 mutation who receives IV/IP paclitaxel/cisplatin — Paul DiSilvestro, MD (28:11)
Case: A woman in her early 60s with BRCA wild-type, HRD-negative peritoneal cancer who received neoadjuvant and adjuvant carboplatin/paclitaxel and now presents with altered mental status and a cerebellar metastasis — Karim ElSahwi, MD (34:40)
Faculty Survey (40:37)
Case: A woman in her early 70s with multiregimen-recurrent endometrioid ovarian adenocarcinoma with a germline PALB2 mutation develops breast cancer during maintenance niraparib — Dr Chase (50:02)
Case: A woman in her late 60s with Stage IV BRCA wild-type, HRD-negative HGSOC develops anemia on maintenance olaparib/bevacizumab — Priya Rudolph, MD (59:25)

CME information and select publications

Breast Cancer | Meet The Professor: Optimizing the Management of HER2-Positive Breast Cancer — Part 1 Sep 22, 2022

Show notes

Featuring perspectives from Dr Mark Pegram, including the following topics:

Introduction: Journal Club with Dr Pegram (0:00)
Case: A woman in her mid 60s with ER/PR-negative, HER2-positive metastatic breast cancer after multiple lines of HER2-directed therapy with no evidence of disease after 8 years of pertuzumab/trastuzumab — Raman Sood, MD (22:35)
Case: A woman in her early 60s with a 1.8-cm triple-positive invasive ductal carcinoma after partial mastectomy/axillary lymph node dissection (9 N+) receives adjuvant TCHP x 6 — Shaachi Gupta, MD, MPH (27:30)
Case: A woman in her early 70s with de novo ER-positive, HER2-positive breast cancer develops asymptomatic, bilateral brain metastases on TCHP — Chris Prakash, MD (36:02)
Case: A woman in her early 30s with ER/PR-positive, HER2-negative breast cancer after neoadjuvant dose-dense doxorubicin and cyclophosphamide -> paclitaxel and bilateral mastectomy, now with HER2-positive disease on repeat testing — Zanetta S Lamar, MD (46:08)
Case: A woman in her mid 40s with triple-negative breast cancer at biopsy declines neoadjuvant therapy and at surgery has a 3.2-cm node-negative, HER2-positive tumor — Alan B Astrow, MD (53:20)

CME information and select publications

Non-Small Cell Lung Cancer | Meet The Professor: Current and Future Management of Non-Small Cell Lung Cancer with an EGFR Mutation — Part 2 Sep 20, 2022

Show notes

Featuring perspectives from Dr Lecia Sequist, including the following topics:

Introduction: Journal Club with Lecia V Sequist, MD, MPH (0:00)
Case: A woman in her early 70s with Stage IIB adenocarcinoma of the lung and an EGFR exon 19 mutation— Adam R Miller, MD (19:26)
Case: A man in his late 70s with metastatic adenocarcinoma of the lung and an EGFR L858R mutation develops hemoptysis from an "escape lesion" on osimertinib — Priya Rudolph, MD, PhD (24:59)
Case: A man in his early 70s with metastatic adenocarcinoma of the lung (PD-L1 high) and an EGFR L858R mutation experiences disease progression on pembrolizumab — Sandip Patel, MD (28:45)
Case: A woman in her mid 60s with metastatic adenocarcinoma of the lung with an EGFR exon 20 insertion with multiple brain and bone metastases (PD-L1
Case: A woman in her mid 50s with metastatic adenocarcinoma of the lung and an EGFR mutation experiences disease progression after response to osimertinib x 3 years (PD-L1 TPS 80%) — Gigi Chen, MD (43:44)
Case: A man in his mid 50s with adenocarcinoma of the lung and an EGFR exon 19 mutation with brain metastases and disease progression on both osimertinib and carboplatin/paclitaxel/pembrolizumab/bevacizumab (ROS fusion detected on RNA assay) — Namrata I Peswani, MD (59:12)

CME information and select publications

Hodgkin Lymphoma | Oncology Today with Dr Neil Love: Current and Future Management of Hodgkin Lymphoma (Companion Faculty Lecture) Sep 15, 2022

Show notes

Featuring a slide presentation and related discussion from Dr Stephen Ansell, including the following topics:

Recent updates in the first-line management of advanced classical Hodgkin lymphoma (0:00)
Emerging data with immune checkpoint inhibitors when combined with current treatment strategies (4:40)
Current and future management of early-stage disease (9:53)
Treatment options for patients with relapsed HL (17:52)
Later-line options for patients with multiply-relapsed disease (24:46)

CME information and select publications

Our TOPPODCAST Picks

Follow Us

Stay Connected

Research To Practice | Oncology Videos

Related Podcasts

Links

Stay Connected